Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Nautilus Biotechnology Price Performance
NASDAQ NAUT opened at $1.47 on Wednesday. Nautilus Biotechnology has a 1 year low of $1.47 and a 1 year high of $3.09. The firm has a market cap of $184.57 million, a price-to-earnings ratio of -2.62 and a beta of 1.21. The company has a fifty day moving average price of $1.75 and a 200-day moving average price of $2.27.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Nautilus Biotechnology stock. Bank of America Corp DE raised its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) by 37.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,419 shares of the company’s stock after acquiring an additional 13,363 shares during the period. Bank of America Corp DE’s holdings in Nautilus Biotechnology were worth $83,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.71% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Stock Report on NAUT
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Featured Stories
- Five stocks we like better than Nautilus Biotechnology
- How to Calculate Stock Profit
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Business Services Stocks Investing
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Is WallStreetBets and What Stocks Are They Targeting?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.